Domestic News: New Products, Regulations, and Technological Innovations
1. Discussion Begins on Health Insurance Coverage for iPS Cell-Derived Products
News Highlights
The Central Social Insurance Medical Council (Chuikyo) has initiated discussions regarding public health insurance coverage for two world-first regenerative medicine products using iPS cells. The two products under consideration are:
- ReHeart (Qualips Inc.): A myocardial cell sheet for cardiac patients, classified as a medical device.
- AMSHEPURI (Sumitomo Pharma Co., Ltd.): Dopaminergic neurons for Parkinson's disease patients, classified as a pharmaceutical product.
Impact on the Industry
It is expected that official prices will be determined as early as this summer, and the products will begin to be used in actual medical settings. This marks a crucial step towards the widespread adoption of iPS cell-based therapies as common medical practice. Further acceleration of business development in the field of regenerative medicine is anticipated.
2. Menicon's Absorbable Bone Regeneration Material "Verte" Obtains Medical Device Approval
News Highlights
Menicon Co., Ltd., in collaboration with Nagoya University and Okayama University, has obtained new domestic medical device approval for "Verte," an absorbable bone regeneration material. This product utilizes self-assembling peptide gel technology and aids in bone regeneration when mixed with autologous bone.
Impact on the Industry
Traditional bone reconstruction surgeries have faced challenges with material compatibility and operability. However, "Verte" possesses characteristics that improve intraoperative operability and postoperative bone fusion rates. As an innovative product that contributes to reducing the burden on physicians and improving patient prognoses, it is expected to be widely utilized in the orthopedic field.
3. Fujifilm Promotes Medical DX and Breast Cancer Screening in Vietnam
News Highlights
Fujifilm Corporation is strengthening its efforts to promote medical DX (Digital Transformation) and the widespread adoption of breast cancer screening in Vietnam. In addition to awareness-raising activities through the introduction of a 3D mammography system at Thang Long Rack Viet International Hospital, the company is also collaborating with local medical institutions to provide human resource development support, such as interpretation training.
Impact on the Industry
This is an excellent example of the “international expansion of Japanese medical technology” that comprehensively supports not only the sale of medical devices but also the improvement of diagnostic systems and the establishment of a preventive medicine culture. It is attracting significant attention as a new business model for medical device manufacturers in emerging markets.
International News: M&A, New Products, Regulatory Trends
1. FDA Approves Waters' “At-Home Cervical Cancer Screening Kit”
News Highlights
The U.S. Food and Drug Administration (FDA) has approved the “Onclarity HPV Self-Collection Kit” developed by Waters Corporation. This product is the first comprehensive HPV (human papillomavirus) test kit that allows patients to collect samples themselves at home.
Impact on the Industry
This is a groundbreaking approval that significantly lowers the barrier to cervical cancer screening, which previously required a visit to a medical institution. It symbolizes the expansion of the at-home testing and self-care market, and it is expected that the trend of “at-home testing and screening” will further strengthen for other diseases in the future.
2. J&J Launches Next-Generation PFA Device "Varipulse Pro" in Europe
News Highlights
Johnson & Johnson has obtained CE Mark approval for its next-generation Pulsed Field Ablation (PFA) device, "Varipulse Pro," used for the treatment of atrial fibrillation, and has commenced its rollout in the European market. This product is capable of performing ablation (tissue cauterization) five times faster than conventional models.
Industry Impact
PFA is a cutting-edge technology that uses electrical pulses instead of heat for safe treatment and is currently one of the most closely watched areas in the cardiovascular field. With the introduction of this product by J&J, competition for market share with rivals such as Medtronic and Boston Scientific is expected to intensify further in Europe.
3. Hologic Completes Privatization and Appoints New CEO
News Highlights
Hologic, a company with a strong focus on women's health, has completed its acquisition (privatization) by Blackstone and TPG, valued at approximately $18.3 billion. Concurrently, former Baxter CEO, Mr. José Almeida, has been appointed as the new Chief Executive Officer (CEO).
Industry Impact
By becoming part of a large private equity firm, Hologic can more easily invest in long-term growth strategies such as innovation creation and mergers and acquisitions, without being influenced by short-term stock market fluctuations. Under the leadership of the new CEO, Mr. Almeida, there is significant industry interest in how the business portfolio will be restructured and what new acquisition strategies will be pursued.
4. UK and US Medical Device Regulators (MHRA and FDA) Strengthen Cooperation
News Highlights
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) and the US FDA have agreed to strengthen their cooperative relationship regarding medical device regulation. Both agencies plan to proceed with discussions, including the establishment of future mutual recognition mechanisms.
Impact on the Industry
As the UK establishes its own regulatory framework post-Brexit, this is a significant move to align with the US, the world's largest medical device market. For medical device manufacturers, this could lead to a more efficient approval process in both countries, potentially enabling faster market entry for innovative devices.
Summary: Key Industry Trends
From today's news, it can be observed that the medical device industry is currently moving along the following three major trends:
- Advancement of patient-centric healthcare and home-based care (e.g., approval of Waters' at-home HPV testing kit)
- Practical application and widespread adoption of advanced technologies (e.g.,動き towards insurance coverage for iPS cell products, J&J's next-generation PFA technology)
- Global industry restructuring and rule-making (e.g., Hologic's massive acquisition, strengthened cooperation between UK and US regulatory authorities)
In particular, the fact that iPS cell-derived products are being discussed for insurance coverage and are becoming established as a common treatment option is a very significant development for Japan's medical industry.
Related Links
- Jiji.com: Discussion Begins on Insurance Coverage for iPS Products
- Menicon: Absorbable Bone Regeneration Material "Verte" Obtains Medical Device Approval
- Medical Excellence JAPAN: Fujifilm's Medical DX Promotion in Vietnam
- Pharmacy Times: FDA Clears First Comprehensive At-Home Cervical Cancer Screening Tool
- Cardiovascular Business: Johnson & Johnson launches faster PFA system in Europe
- MedTech Dive: Hologic hires former Baxter leader José Almeida as CEO
- GOV.UK: UK and US deepen regulatory cooperation on medical devices
Need help with Japan's medical device approval?
Our regulatory affairs consultants specializing in digestive endoscopy devices provide end-to-end support from strategy to document preparation. Contact us for a free initial consultation.
Free Consultation